泰国的 III 期 HIV 疫苗试验：迈向 HIV 保护疫苗的一步。
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
机构信息
Animal Models and Retroviral Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104.
Abstract
The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.
摘要
泰国开展的大型人类功效试验 RV144 于 2009 年夏得出结论。这是首个表明在预防 HIV 感染方面具有一定但显著效果的 III 期试验。该试验标志着预防 HIV 的疫苗可能成为现实。在泰国进行的疫苗试验方案包括使用携带三种合成 HIV 基因的金丝雀痘载体进行初级免疫，随后用两种来自 HIV clade B 和 E 的重组包膜蛋白进行加强免疫。为了解该疫苗组合诱导的新反应在预防 HIV 感染方面的作用，许多研究人员齐聚一堂，共同目标是研发出安全有效的 HIV 疫苗。
相似文献
1
Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
Expert Rev Vaccines. 2010 Sep;9(9):997-1005. doi: 10.1586/erv.10.104.
2
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
Lancet HIV. 2020 Apr;7(4):e238-e248. doi: 10.1016/S2352-3018(19)30406-0. Epub 2020 Feb 6.
3
HIV-1 prophylactic vaccine trials in Thailand.
Curr HIV Res. 2005 Jan;3(1):17-30. doi: 10.2174/1570162052772933.
4
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.
5
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
J Infect Dis. 2004 Apr 1;189(7):1221-31. doi: 10.1086/382088. Epub 2004 Mar 15.
6
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
J Infect Dis. 2012 Aug 1;206(3):431-41. doi: 10.1093/infdis/jis367. Epub 2012 May 25.
7
An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hum Vaccin. 2010 Oct;6(10):835-40. doi: 10.4161/hv.6.10.12635. Epub 2010 Oct 1.
8
Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Virol J. 2011 Sep 7;8:429. doi: 10.1186/1743-422X-8-429.
9
Human immunodeficiency virus vaccine trials.
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a007351. doi: 10.1101/cshperspect.a007351.
10
Nonreplicating vectors in HIV vaccines.
Curr Opin HIV AIDS. 2013 Sep;8(5):412-20. doi: 10.1097/COH.0b013e328363d3b7.
引用本文的文献
1
Enhanced HIV immune responses elicited by an apoptotic single-cycle SHIV lentivector DNA vaccine.
Front Cell Infect Microbiol. 2025 Apr 10;15:1481427. doi: 10.3389/fcimb.2025.1481427. eCollection 2025.
2
Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.
Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368.
3
Personal experiences following acquiring HIV infection while volunteering in Phase I/II HIV vaccine trials: A qualitative study from Tanzania.
PLoS One. 2022 Oct 26;17(10):e0276404. doi: 10.1371/journal.pone.0276404. eCollection 2022.
4
SARS-CoV-2 Vaccine Development: An Overview and Perspectives.
ACS Pharmacol Transl Sci. 2020 Sep 18;3(5):844-858. doi: 10.1021/acsptsci.0c00109. eCollection 2020 Oct 9.
5
CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine.
Vaccine. 2020 Mar 4;38(11):2626-2635. doi: 10.1016/j.vaccine.2020.01.023. Epub 2020 Feb 10.
6
Using Mobile Technology (pMOTAR) to Assess Reactogenicity: Protocol for a Pilot Randomized Controlled Trial.
JMIR Res Protoc. 2018 Oct 3;7(10):e175. doi: 10.2196/resprot.9396.
7
Mucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques.
PLoS One. 2018 Aug 28;13(8):e0202997. doi: 10.1371/journal.pone.0202997. eCollection 2018.
8
Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines.
AIDS Res Ther. 2017 Sep 12;14(1):47. doi: 10.1186/s12981-017-0176-5.
9
Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
Expert Rev Vaccines. 2017 Oct;16(10):973-985. doi: 10.1080/14760584.2017.1371594. Epub 2017 Sep 4.
10
Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
Virol J. 2017 Aug 23;14(1):163. doi: 10.1186/s12985-017-0831-4.
本文引用的文献
1
Raft of results energizes researchers.
IAVI Rep. 2009 Sep-Oct;13(5):4-5, 7-13, 17.
2
Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America.
Mol Biol Evol. 2010 Feb;27(2):417-25. doi: 10.1093/molbev/msp254. Epub 2009 Oct 28.
3
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
4
AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.
Vaccine. 2009 Feb 11;27(7):1136-40. doi: 10.1016/j.vaccine.2008.11.071. Epub 2008 Dec 9.
5
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.
6
The use of nonhuman primate models in HIV vaccine development.
PLoS Med. 2008 Aug 12;5(8):e173. doi: 10.1371/journal.pmed.0050173.
7
HIV vaccine research in Thailand: lessons learned.
Expert Rev Vaccines. 2008 Apr;7(3):311-7. doi: 10.1586/14760584.7.3.311.
8
A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.
J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):48-55. doi: 10.1097/QAI.0b013e3181354bd7.
9
The spread of HIV-1 subtypes B and CRF01_AE among injecting drug users in Bangkok, Thailand.
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):468-75. doi: 10.1097/QAI.0b013e318093dea5.
10
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
J Infect Dis. 2006 Dec 15;194(12):1661-71. doi: 10.1086/508748. Epub 2006 Nov 3.
Zotero 插件